Shares of health-care companies ticked down after mixed earnings from one drug giant. Shares of Pfizer were flat after it reported second-quarter revenue short of Wall Street targets, hurt by intensified competition from off-brand, generic versions of some products. Pfizer said it's holding off on acquisitions until the tax regime becomes clear before making decisions on a major acquisition of the kind that some analysts say it needs to reignite growth. India's cabinet rejected Chinese company Fosun Pharmaceuticals' $1.3 billion purchase of domestic drug maker Gland Pharma, The Wall Street Journal reported.
Continue Reading Below
-Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
August 01, 2017 16:18 ET (20:18 GMT)